| Literature DB >> 25517750 |
Gaurav Kumar Pandey1, Sanhita Mitra1, Santhilal Subhash1, Falk Hertwig2, Meena Kanduri3, Kankadeb Mishra1, Susanne Fransson4, Abiarchana Ganeshram1, Tanmoy Mondal1, Sashidhar Bandaru5, Malin Ostensson4, Levent M Akyürek5, Jonas Abrahamsson6, Susan Pfeifer7, Erik Larsson5, Leming Shi8, Zhiyu Peng9, Matthias Fischer2, Tommy Martinsson4, Fredrik Hedborg10, Per Kogner11, Chandrasekhar Kanduri12.
Abstract
Neuroblastoma is an embryonal tumor of the sympathetic nervous system and the most common extracranial tumor of childhood. By sequencing transcriptomes of low- and high-risk neuroblastomas, we detected differentially expressed annotated and nonannotated long noncoding RNAs (lncRNAs). We identified a lncRNA neuroblastoma associated transcript-1 (NBAT-1) as a biomarker significantly predicting clinical outcome of neuroblastoma. CpG methylation and a high-risk neuroblastoma associated SNP on chromosome 6p22 functionally contribute to NBAT-1 differential expression. Loss of NBAT-1 increases cellular proliferation and invasion. It controls these processes via epigenetic silencing of target genes. NBAT-1 loss affects neuronal differentiation through activation of the neuronal-specific transcription factor NRSF/REST. Thus, loss of NBAT-1 contributes to aggressive neuroblastoma by increasing proliferation and impairing differentiation of neuronal precursors.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25517750 DOI: 10.1016/j.ccell.2014.09.014
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743